Skip to main content
. 2017 Feb 22;9(2):547–555. doi: 10.18632/aging.101177

Table 3. The associations between the MT-2A rs10636 polymorphism and clinical characteristics of BC patients.

Variables GG(%) GC(%) p OR(95%CI) CC(%) p OR(95%CI) GC+CC (%) p OR(95%CI)
Tumor size
<2CM 57(37.5) 54(35.5) 41(27) 95(62.5)
≥2CM 98(31.9) 104(33.9) 0.63 1.12(0.71-1.78) 105(34.2) 0.11 1.49(0.92-2.42) 209(68.1) 0.23 1.2(0.85-1.92)
LN metastasis
Negative 64(34.8) 65(35.3) 55(30) 120(65.2)
Positive 84(30.5) 103(37.5) 0.41 1.2(0.77-1.89) 88(32) 0.41 1.22(0.76-1.95) 191(69.5) 0.34 1.2(0.82-1.8
ER
Negative 77(38.1) 63(31.2) 62(30.7) 125(61.9)
Positive 79(30.4) 91(35.4) 0.135 1.41(0.9-2.21) 87(33.9) 0.174 1.3(0.87-2.15) 178(69.3) 0.1 1.3(0.94-2.05)
PR
Negative 90(43.3) 96(46.2) 22(10.5) 118(56.7)
Positive 111(44.2) 106(42.2) 0.58 0.90(0.61-1.33) 34(13.5) 0.46 1.25(0.69-2.29) 140(55.8) 0.84 0.96(0.66-1.39)
Her-2
Negative 100(30.3) 112(33.9) 118(35.8) 230(69.7)
Positive 47(36.4) 44(34.1) 0.48 0.84(0.51-1.37) 38(29.5) 0.14 0.69(0.41-1.13) 82(63.6) 0.21 0.76(0.49-1.16)
Ki-67
<50% 80(27.2) 85(28.9) 129(43.9) 214(72.8)
≥50% 42(25.5) 47(28.5) 0.84 1.05 (0.63-1.77 ) 76(46.1) 0.63 1.12 (0.7-1.79 ) 123(74.5) 0.68 1.1 (0.71-1.69 )
Histological grade
SBR 1-2 65(26.6) 85(34.8) 94(38.5) 179(73.4)
SBR 3 79(36.7) 83(38.6) 0.34 0.8 (0.51-1.26 ) 53(24.6) 0.001 0.46 (0.29-0.74 ) 136(63.3) 0.02 0.63 (0.42-0.93 )
Venous Invasion
Non-little 34(11.6) 64(21.9) 194(66.4) 258(88.4)
Moderate-severe 24(14.4) 65(38.9) 0.25 1.44 (0.77-2.69 ) 78(46.7) 0.06 0.57 (0.32-1.02 ) 143(85.6) 0.4 0.79 (0.45-1.38 )

LN: Axillary lymph node; ER: Estrogen receptor; PR: Progesterone receptor; Her-2: human epidermal growth factor receptor 2; SBR: Scarff, Bloom and Richardson tumor grade